BIIB logo

Biogen Inc.

BIIB
Healthcare|Drug Manufacturers - General|US
$248.35
+4.42 (+1.81%)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82

Analyst Consensus

Buy49 analysts
Strong Buy
0
Buy
33
Hold
15
Sell
1
Strong Sell
0
Consensus Target
$255.00
Implied Upside
+2.7%
Low Target
$175.00
High Target
$300.00

Price Target Trend

Last Month
$269.63
8 targets · +9% vs price
Last Quarter
$259.64
14 targets · +5% vs price
Last Year
$226.26
61 targets · -9% vs price
All Time
$247.81
155 targets · -0% vs price

Rating Trend

Dec 25
16 buy · 19 hold · 1 sell
Jan 26
16 buy · 18 hold · 1 sell
Feb 26
16 buy · 20 hold · 1 sell
Mar 26
15 buy · 20 hold · 1 sell
Apr 26
20 buy · 20 hold · 1 sell
May 26
21 buy · 16 hold · 1 sell
Jun 26
21 buy · 15 hold · 1 sell
Jul 26
23 buy · 14 hold · 1 sell
Aug 26
24 buy · 12 hold · 1 sell
Sep 26
23 buy · 12 hold · 1 sell
Oct 26
25 buy · 12 hold · 1 sell
Nov 26
25 buy · 10 hold · 1 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 2, 2026GuggenheimYatin Suneja$300.00(+18%)$253.62StreetInsider
Oct 29, 2026RBC Capital$272.00(+8%)$251.63TheFly
Oct 29, 2026Wedbush$225.00(-11%)$252.58TheFly
Oct 29, 2026Argus ResearchJasper Hellweg$280.00(+11%)$252.41StreetInsider
Oct 29, 2026UBS$300.00(+19%)$252.31TheFly
Oct 29, 2026Robert W. Baird$290.00(+19%)$244.05TheFly
Oct 12, 2026BMO Capital$220.00(-6%)$232.95TheFly
Oct 9, 2026UBS$270.00(+21%)$223.25TheFly
Oct 8, 2026RBC Capital$256.00(+16%)$219.91TheFly
Sep 10, 2026Stifel NicolausPaul Matteis$242.00(+13%)$214.77StreetInsider
Sep 10, 2026HSBC$175.00(-17%)$210.73TheFly
Sep 3, 2026Piper Sandler$245.00(+10%)$222.67TheFly
Aug 25, 2026RBC Capital$260.00(+19%)$218.12TheFly
Aug 13, 2026Wolfe Research$300.00(+44%)$208.87TheFly
Jul 30, 2026Morgan StanleyTerence Flynn$231.00(+12%)$206.50TheFly
Jul 30, 2026H.C. Wainwright$251.00(+22%)$205.74TheFly
Jul 30, 2026RBC Capital$240.00(+18%)$204.10TheFly
Jul 30, 2026UBS$240.00(+17%)$204.62TheFly
Jul 30, 2026Canaccord Genuity$248.00(+19%)$209.23TheFly
Jul 29, 2026OppenheimerJay Olson$300.00(+43%)$209.23StreetInsider

Recent Rating Actions

FirmActionRatingDate
GuggenheimmaintainBuyNov 2, 2026
HC Wainwright & Co.maintainBuyNov 2, 2026
Canaccord GenuitymaintainBuyOct 29, 2026
NeedhammaintainBuyOct 29, 2026
BairdmaintainOutperformOct 29, 2026
UBSmaintainBuyOct 29, 2026
Truist SecuritiesmaintainBuyOct 29, 2026
WedbushmaintainNeutralOct 29, 2026
TD CowenmaintainBuyOct 29, 2026
Morgan StanleymaintainEqual WeightOct 29, 2026
RBC CapitalmaintainOutperformOct 29, 2026
Argus ResearchupgradeHold →BuyOct 29, 2026
BarclaysmaintainEqual WeightOct 28, 2026
B of A SecuritiesmaintainNeutralOct 22, 2026
TD CowenmaintainBuyOct 21, 2026
Wells FargomaintainOverweightOct 20, 2026
JP MorganupgradeNeutral →OverweightOct 12, 2026
UBSmaintainBuyOct 9, 2026
RBC CapitalmaintainOutperformOct 8, 2026
HSBCmaintainReduceSep 10, 2026
Piper SandlermaintainOverweightSep 3, 2026
RBC CapitalmaintainOutperformAug 25, 2026
Wolfe ResearchupgradePeer Perform →OutperformAug 13, 2026
MizuhomaintainOutperformAug 4, 2026
CitigroupmaintainNeutralAug 3, 2026

Earnings History

Next report: Feb 5, 2027 · EPS est. $2.85
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 28, 2026$2.62$1.99$2.80B$2.63B
Jul 29, 2026$3.60$2.94$2.74B$2.46B
Apr 29, 2026$3.57$3.05$2.48B$2.29B
Feb 6, 2026$1.99$1.63$2.28B$2.20B
Oct 30, 2025$4.81$3.88$2.45B$2.34B
Jul 31, 2025$5.47$3.90$2.65B$2.33B
May 1, 2025$3.02$2.90$2.43B$2.23B
Feb 12, 2025$3.44$3.43$2.45B$2.41B

News

Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)

TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth, subject to individual plan eligibility and reimbursement requirements. “Reimbursement decisions from private payers help determine whether a treatment is a real option for families,” said Claire Zlobin, Founder, Life With A Baby. “It's exciting to see that most p.

Nov 5, 2026businesswire.com
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results

Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.

Oct 29, 2026benzinga.com
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration Presentations across Biogen's Alzheimer's disease…

Oct 29, 2026globenewswire.com
Biogen Q3 Earnings Call Highlights

Biogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said the company remains on track to return to top-line growth in 2026 and raised the lower end of its full-year non-GAAP diluted earnings-per-share guidance.

Oct 28, 2026marketbeat.com
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript

Biogen Inc. ( BIIB ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - Executive VP & Head of Development Robin Kramer - Executive VP & CFO Alisha Alaimo - President & Head of North America Conference Call Participants Philip Nadeau - TD Cowen, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Di…

Oct 28, 2026seekingalpha.com
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.

Oct 28, 2026zacks.com
Big Day for Econ Data, Hyperscaler Earnings

We have a solid slate of reports today, both of the earnings variety and regarding economic growth.

Oct 28, 2026zacks.com
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Oct 28, 2026zacks.com
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates

Biogen Inc. (BIIB) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $4.81 per share a year ago.

Oct 28, 2026zacks.com
Biogen Swings to Loss, Logs Higher Sales

The biotechnology company said the swing to a loss was primarily due to transaction-related charges.

Oct 28, 2026wsj.com
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?

Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.

Oct 26, 2026zacks.com
Baron Health Care Fund: Q3 2026 New Positions And Exits

During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor's clinical trial readout.

Oct 26, 2026seekingalpha.com
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?

Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Oct 23, 2026zacks.com
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential wit

Oct 22, 2026gurufocus.com
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm

Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts and improving growth portfolio performance. MS franchise and Alzheimer's therapies face patent expiries, competition, and limited efficacy, pressuring BIIB to deliver new blockbuster products. Growth hinges on pipeline readouts, especially litifilimab in SLE, while subQ Leqembi, Spinraza high dose, Syfovre, and Empaveli are key near-term revenue drivers.

Oct 21, 2026seekingalpha.com
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oct 21, 2026zacks.com
A Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10

On October 20, 2026, Biogen Inc (BIIB) shares rose 4.1% to a current price of $243.10. This increase comes in the context of a 52-week range that saw lows of $1

Oct 20, 2026gurufocus.com
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.

Oct 20, 2026zacks.com
Biogen Inc. $BIIB Shares Acquired by CWA Asset Management Group LLC

CWA Asset Management Group LLC raised its holdings in Biogen Inc. (NASDAQ: BIIB) by 11.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,412 shares of the biotechnology company's stock after acquiring an additional 4,285 shares during

Oct 20, 2026defenseworld.net
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking place from October 22 to 25, 2026 in Denver, Colorado.

Oct 19, 2026globenewswire.com